Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
25 participants
OBSERVATIONAL
2013-07-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Melatonin in Acute Stroke
NCT03843008
Pulmonary Infection After Ischemic Stroke
NCT05923034
COlchicine iN Circulating Inflammatory Markers After StrokE (CONCISE)
NCT06062277
Prospective Cohort Control Study on Changes in Gut Microbiota in Ischemic Stroke
NCT07247838
Screening of New Markers of Gut Microbiota in Stroke and Depression: a Cross-sectional Study
NCT06379464
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged ≥ 18 years of age
* Neuroimaging or clinical symptoms are consistent with an acute ischemic stroke (AIS)
* There are no alternative explanations for symptoms (eg. tumor, witnessed seizure, history of complicated migraine headache, hypoglycemia \[blood sugar (BS) \< 50 mg/dL\] or hyperglycemia (BS \> 400 mg/dL)
* Subject is able to be enrolled and have blood samples drawn (Note: inability to provide a sample within 48 hours does not preclude inclusion if consent is provided after this time and patient can provide blood at subsequent time points (see Table)
* Subject is able to provide informed consent for participation in this research study
Exclusion Criteria
* Current diagnosis of or treatment for major depressive disorder
* Women who are pregnant at the time of stroke, since pregnancy alters inflammatory markers
* Communication problems due to aphasia at visit 2, inability to speak English
* History of substance abuse and other relevant psychiatric conditions
* Autoimmune, current or recent infection, hematological disorders, use of immune modulating drugs
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexander Kusnecov, Ph.D.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alexander Kusnecov, Ph.D.
Professor of Psychology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James S McKinney, MD
Role: PRINCIPAL_INVESTIGATOR
Rutgers University
Alexander Kusnecov, PhD
Role: STUDY_DIRECTOR
Rutgers University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rutgers, The State University
New Brunswick, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
pc 62-12
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2012001658
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.